GABAA Receptor α Subunits Differentially Contribute to Diazepam Tolerance after Chronic Treatment
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Within the GABA(A)-receptor field, two important questions are what molecular mechanisms underlie benzodiazepine tolerance, and whether tolerance can be ascribed to certain GABA(A)-receptor subtypes. METHODS: We investigated tolerance to acute anxiolytic, hypothermic and sedative effects of diazepam in mice exposed for 28-days to non-selective/selective GABA(A)-receptor positive allosteric modulators: diazepam (non-selective), bretazenil (partial non-selective), zolpidem (α(1) selective) and TPA023 (α(2/3) selective). In-vivo binding studies with [(3)H]flumazenil confirmed compounds occupied CNS GABA(A) receptors. RESULTS: Chronic diazepam treatment resulted in tolerance to diazepam's acute anxiolytic, hypothermic and sedative effects. In mice treated chronically with bretazenil, tolerance to diazepam's anxiolytic and hypothermic, but not sedative, effects was seen. Chronic zolpidem treatment resulted in tolerance to diazepam's hypothermic effect, but partial anxiolytic tolerance and no sedative tolerance. Chronic TPA023 treatment did not result in tolerance to diazepam's hypothermic, anxiolytic or sedative effects. CONCLUSIONS: OUR DATA INDICATE THAT: (i) GABA(A)-α(2)/α(3) subtype selective drugs might not induce tolerance; (ii) in rodents quantitative and temporal variations in tolerance development occur dependent on the endpoint assessed, consistent with clinical experience with benzodiazepines (e.g., differential tolerance to antiepileptic and anxiolytic actions); (iii) tolerance to diazepam's sedative actions needs concomitant activation of GABA(A)-α(1)/GABA(A)-α(5) receptors. Regarding mechanism, in-situ hybridization studies indicated no gross changes in expression levels of GABA(A) α(1), α(2) or α(5) subunit mRNA in hippocampus or cortex. Since selective chronic activation of either GABA(A) α(2), or α(3) receptors does not engender tolerance development, subtype-selective GABA(A) drugs might constitute a promising class of novel drugs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Benzodiazepine actions mediated by specific γ-aminobutyric acidA receptor subtypes
Rudolph, U., Crestani, F., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Martin, J. R., Bluethmann, H., & Möhler, H. (1999) · Nature · doi:10.1038/44579 · Cited by 1,172
McKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
GABA-based therapeutic approaches: GABAA receptor subtype functions
RUDOLPH, U., & MOHLER, H. (2006) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2005.10.003 · Cited by 499 · cited 3×
“In the present study, we investigated whether differential tolerance develops to the anxiolytic-like, hypothermic and sedative effects of acute diazepam administration in mice treated chronically for 28 days with various GABAA receptor PAMs with different affinity and/or functional selectivity for GABAA receptor subty…”
BackgroundReversal of pathological pain through specific spinal GABAA receptor subtypes
Knabl, J., Witschi, R., Hösl, K., Reinold, H., Zeilhofer, U. B., Ahmadi, S., Brockhaus, J., Sergejeva, M., Hess, A., Brune, K., et al. (2008) · Nature · doi:10.1038/nature06493 · Cited by 438
Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal
Bateson, A. (2002) · Current Pharmaceutical Design · doi:10.2174/1381612023396681 · Cited by 240
Regulation of GABAA Receptor Subunit Expression by Pharmacological Agents
Uusi-Oukari, M., & Korpi, E. R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002063 · Cited by 213
Rowlett, J. K., Platt, D. M., Lelas, S., Atack, J. R., & Dawson, G. R. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405621102 · Cited by 212
Vinkers, C. H., & Olivier, B. (2012) · Advances in Pharmacological Sciences · doi:10.1155/2012/416864 · Cited by 195 · cited 2×
“, anxiety, hypothermia or hypolocomotion) [3].”
Self-citationAtack, J. R., Wafford, K. A., Tye, S. J., Cook, S. M., Sohal, B., Pike, A., Sur, C., Melillo, D., Bristow, L., Bromidge, F., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089920 · Cited by 188
de Haas, S. L., de Visser, S. J., van der Post, J. P., de Smet, M., Schoemaker, R. C., Rijnbeek, B., Cohen, A. F., Vega, J. M., Agrawal, N. G. B., Goel, T. V., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106072343 · Cited by 84 · cited 1×
“addition to GABAA-a2/a3 selective compounds’ reduced propensity to engender sedation and postural instability [64].”
BackgroundAli, N. J., & Olsen, R. W. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00664.x · Cited by 67 · cited 1×
“In addition to suggestions that tolerance development might reflect reduced allosteric interaction between the benzodiazepine and GABA binding sites [56,57,58], future studies on compensatory changes distal to the GABAA receptor after chronic treatment with GABAA receptor PAMs, including second messenger systems (e.”
BackgroundAtor, N. A., Atack, J. R., Hargreaves, R. J., Burns, H. D., & Dawson, G. R. (2010) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.109.158303 · Cited by 66
Primus, R. J., Yu, J., Xu, J., Hartnett, C., Meyyappan, M., Kostas, C., Ramabhadran, T. V., & Gallager, D. W. (1996) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)12410-5 · Cited by 60 · cited 1×
“In addition to suggestions that tolerance development might reflect reduced allosteric interaction between the benzodiazepine and GABA binding sites [56,57,58], future studies on compensatory changes distal to the GABAA receptor after chronic treatment with GABAA receptor PAMs, including second messenger systems (e.”
BackgroundDiazepam‐induced adaptive plasticity revealed by α1 GABAA receptor‐specific expression profiling
Huopaniemi, L., Keist, R., Randolph, A., Certa, U., & Rudolph, U. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02216.x · Cited by 58 · cited 1×
“, [59]) or changes in excitatory amino acid systems [60], might shed more light on mechanisms underlying tolerance development.”
BackgroundAtack, J. R. (2009) · Advances in Pharmacology · doi:10.1016/s1054-3589(08)57004-9 · Cited by 52 · cited 3×
“In the present study, we investigated whether differential tolerance develops to the anxiolytic-like, hypothermic and sedative effects of acute diazepam administration in mice treated chronically for 28 days with various GABAA receptor PAMs with different affinity and/or functional selectivity for GABAA receptor subty…”
BackgroundMirza, N. R., & Nielsen, E. Ø. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.094474 · Cited by 38 · cited 1×
“ED50 values were comparable to published data [27].”
ResultSelf-citationAllison, C., & Pratt, J. A. (2006) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300800 · Cited by 27
Cited by
Rudolph, U., & Möhler, H. (2014) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-011613-135947 · Cited by 319
Han, S., Tai, C., Jones, C. J., Scheuer, T., & Catterall, W. A. (2014) · Neuron · doi:10.1016/j.neuron.2014.01.016 · Cited by 231
GABAergic Control of Depression-Related Brain States
Luscher, B., & Fuchs, T. (2015) · Advances in Pharmacology · doi:10.1016/bs.apha.2014.11.003 · Cited by 149
“…this phenomenon include the fact that benzodiazepines induce rapid tolerance and also increase lysosomal degradation of major subtypes of GABAARs, rendering these drugs unsuitable for long-term therapies (Jacob et al., 2012; Vinkers et al., 2012), although they are highly effective as anxiolytics.”
BackgroundCheng, T., Wallace, D. M., Ponteri, B. B., & Tuli, M. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s164307 · Cited by 66
Chronic diazepam administration increases the expression of Lcn2 in the CNS
Furukawa, T., Shimoyama, S., Miki, Y., Nikaido, Y., Koga, K., Nakamura, K., Wakabayashi, K., & Ueno, S. (2017) · Pharmacology Research & Perspectives · doi:10.1002/prp2.283 · Cited by 31
“Although BZDs are frequently prescribed because of their high efficacy and low toxicity, there are significant risks associated with their long-term use, such as tolerance, dependence, withdrawal, and cognitive and learning impairment (Golombok et al. 1988; Rummans et al. 1993; Zeng and Tietz 1999; Paterniti et al. 20…”
Background
Metadata
- Authors
- Vinkers, C. H., van Oorschot, R., Nielsen, E. Ø., Cook, J. M., Hansen, H. H., Groenink, L., Olivier, B., & Mirza, N. R.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2012-08-13
- Volume
- 7
- Issue
- 8
- Pages
- e43054
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2031990844
- Cited by
- 47
- References
- 17
- FWCI
- 1.20
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.